Indium-111-DOTA-lanreotide: biodistribution, safety and radiation absorbed dose in tumor patients.
Abstract | UNLABELLED: Imaging with radiolabeled somatostatin/ vasoactive intestinal peptide analogs has recently been established for the localization diagnosis of a variety of human tumors including neuroendocrine tumors, intestinal adenocarcinomas and lymphomas. This study reports on the biodistribution, safety and radiation absorbed dose of 111In-1,4,7,10-tetraazacyclododecane-N,N',N",N'''-tetraacetic acid ( DOTA)- lanreotide, a novel peptide tracer, which identifies hSST receptor (R) subtypes 2 through 5 with high affinity, and hSSTR1 with low affinity. METHODS: RESULTS: After an initial rapid blood clearance [results of biexponential fits: T(eff1) 0.4 min (fraction a1 80%) and T(eff2) 13 min (fraction a2 14%)], the radioactivity was excreted into the urine and amounted to 42% +/- 3% of the injected dose (%ID) within 24 hr and 62% +/- 6%ID within 72 hr after injection of 111In-DOTA-lanreotide. In all patients, tumor sites were visualized during the initial minutes after injection of 111In-DOTA-lanreotide. The mean radiation absorbed dose amounted to 1.2 (range 0.21-5.8) mGy/MBq for primary tumors and/or metastases. The effective half-lives of 111In-DOTA-lanreotide in the tumors were T(eff1) 4.9 +/- 2.2 and T(eff2) 37.6 +/- 6.6 hr, and the mean residence time tau was 1.8 hr. The highest radiation absorbed doses were calculated for the spleen (0.39 +/- 0.13 mGy/MBq), kidneys (0.34 +/- 0.08 mGy/MBq), urinary bladder (0.21 +/- 0.03 mGy/MBq) and liver (0.16 +/- 0.04 mGy/MBq). The effective dose was 0.11 +/- 0.01 (range 0.09-0.12) mSv/MBq. During the observation period of 72 hr, no side effects were noted after 111In-DOTA-lanreotide application. The 111In-DOTA-lanreotide radiation absorbed tumor dose was significantly higher (ratio 2.25 +/- 0.60, p < 0.01) when directly compared with 111In-OCT. CONCLUSION:
|
Authors | I Virgolini, I Szilvasi, A Kurtaran, P Angelberger, M Raderer, E Havlik, F Vorbeck, C Bischof, M Leimer, G Dorner, K Kletter, B Niederle, W Scheithauer, P Smith-Jones |
Journal | Journal of nuclear medicine : official publication, Society of Nuclear Medicine
(J Nucl Med)
Vol. 39
Issue 11
Pg. 1928-36
(Nov 1998)
ISSN: 0161-5505 [Print] United States |
PMID | 9829585
(Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Indium Radioisotopes
- Peptides, Cyclic
- lanreotide
- Somatostatin
- Octreotide
|
Topics |
- Adenocarcinoma
(diagnostic imaging)
- Adult
- Aged
- Carcinoid Tumor
(diagnostic imaging)
- Female
- Half-Life
- Humans
- Indium Radioisotopes
(pharmacokinetics)
- Lymphoma
(diagnostic imaging)
- Male
- Middle Aged
- Neuroendocrine Tumors
(diagnostic imaging)
- Octreotide
(pharmacokinetics)
- Peptides, Cyclic
(pharmacokinetics)
- Radiometry
- Somatostatin
(analogs & derivatives, pharmacokinetics)
- Tissue Distribution
- Tomography, Emission-Computed, Single-Photon
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|